We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · July 22, 2020

Extremely Low Risk of HCC Development in Patients With Chronic Hepatitis B in Immune-Tolerant Phase

Alimentary Pharmacology & Therapeutics

 

Additional Info

Alimentary Pharmacology & Therapeutics
Extremely Low Risk of Hepatocellular Carcinoma Development in Patients With Chronic Hepatitis B in Immune-Tolerant Phase
Aliment. Pharmacol. Ther. 2020 Jul 01;52(1)196-204, HA Lee, HW Lee, IH Kim, SY Park, DH Sinn, JH Yu, YS Seo, SH Um, JI Lee, KS Lee, CH Lee, WY Tak, YO Kweon, W Kang, YH Paik, JW Lee, SJ Suh, YK Jung, BK Kim, JY Park, DY Kim, SH Ahn, KH Han, HJ Yim, SU Kim

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading